» Articles » PMID: 7538161

Prognostic Significance of Proteolytic Enzymes in Human Brain Tumors

Overview
Journal J Neurooncol
Publisher Springer
Date 1994 Jan 1
PMID 7538161
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Proteases and their inhibitors have been shown to play roles in tumor invasion and metastasis in a number of experimental models. Recently, relative increases in the amounts of urokinase type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) in tumor samples have been correlated with poorer, pathological grade, shorter disease-free interval, and shorter survival. To date, all studies investigating the prognostic significance of proteases and their inhibitors have been limited to extracranial cancer. In this article, we review the literature and present our data on the prognostic significance of proteases in human brain tumors. High levels of uPA were seen in malignant glioma and metastatic tumors (n = 82), whereas normal levels of uPA were found in low-grade gliomas. Analysis with magnetic resonance imaging (MRI) demonstrated a significant correlation between high levels of uPA and necrosis and edema (n = 50; P < 0.05). Similarly, patients with high levels of uPA had shorter survival than did patients with low levels of uPA. Tissue-type plasminogen activator (tPA), which was virtually absent in glioblastoma multiforme (GBM), colon lung, and breast metastasis, was found in normal quantities in anaplastic astrocytoma (AA), low-grade glioma (LGG), and meningioma. Melanoma had significantly more tPA activity than normal brain did. A reverse correlation was found between tPA and MRI findings of necrosis, enhancement, and edema. Similarly, patients with no detectable tPA activity had shorter survival than did patients with detectable tPA activity. We conclude that high levels of uPA and absent tPA activity correlate with histologically malignant brain tumors, aggressive characteristics, and shorter survival.

Citing Articles

Urokinase Plasminogen Activator Receptor: An Important Focal Player in Chronic Subdural Hematoma?.

Jensen T, Olsen M, Lelkaitis G, Kjaer A, Binderup T, Fugleholm K Inflammation. 2024; 47(3):1015-1027.

PMID: 38236383 PMC: 11147925. DOI: 10.1007/s10753-023-01957-5.


To Explore the Stem Cells Homing to GBM: The Rise to the Occasion.

Tsibulnikov S, Drefs N, Timashev P, Ulasov I Biomedicines. 2022; 10(5).

PMID: 35625723 PMC: 9138893. DOI: 10.3390/biomedicines10050986.


Diffuse vertebral metastases from glioblastoma with vertebroepidural diffusion: A case report and review of the literature.

Colamaria A, Blagia M, Sacco M, Carbone F Surg Neurol Int. 2021; 12:437.

PMID: 34513200 PMC: 8422500. DOI: 10.25259/SNI_538_2021.


Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme.

Tilak M, Holborn J, New L, Lalonde J, Jones N Int J Mol Sci. 2021; 22(4).

PMID: 33673213 PMC: 7918566. DOI: 10.3390/ijms22041831.


Is DNA Methylation a Ray of Sunshine in Predicting Meningioma Prognosis?.

Shen L, Lin D, Cheng L, Tu S, Wu H, Xu W Front Oncol. 2020; 10:1323.

PMID: 33014773 PMC: 7498674. DOI: 10.3389/fonc.2020.01323.


References
1.
OSSOWSKI L, Reich E . Antibodies to plasminogen activator inhibit human tumor metastasis. Cell. 1983; 35(3 Pt 2):611-9. DOI: 10.1016/0092-8674(83)90093-4. View

2.
Pedersen P, Marienhagen K, Mork S, Bjerkvig R . Migratory pattern of fetal rat brain cells and human glioma cells in the adult rat brain. Cancer Res. 1993; 53(21):5158-65. View

3.
Rutka J, Myatt C, Giblin J, Davis R, Rosenblum M . Distribution of extracellular matrix proteins in primary human brain tumours: an immunohistochemical analysis. Can J Neurol Sci. 1987; 14(1):25-30. DOI: 10.1017/s0317167100026123. View

4.
Olson D, Pollanen J, Hoyer-Hansen G, Ronne E, Sakaguchi K, Wun T . Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J Biol Chem. 1992; 267(13):9129-33. View

5.
Andreasen P, Nielsen L, Kristensen P, Skriver L, Dano K . Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem. 1986; 261(17):7644-51. View